These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33370026)

  • 1. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.
    Takahashi H; Ikeda M; Shiba S; Imaoka H; Todaka A; Shioji K; Yane K; Kojima Y; Kobayashi S; Asagi A; Ozaka M; Takada R; Nagashio Y; Horiguchi S; Kasuga A; Suzuki E; Terashima T; Ueno M; Morizane C; Furuse J
    Pancreas; 2021 Jan; 50(1):77-82. PubMed ID: 33370026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen.
    Yoo C; Kim BJ; Kim KP; Lee JL; Kim TW; Ryoo BY; Chang HM
    Cancer Res Treat; 2017 Jul; 49(3):759-765. PubMed ID: 27857025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
    Busch E; Werft W; Bougatf N; Hackert T; Jäger D; Springfeld C; Berger AK
    Pancreas; 2021 Mar; 50(3):300-305. PubMed ID: 33835959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
    Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
    World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
    Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
    Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
    Nakano S; Yuki S; Kawamoto Y; Nakatsumi H; Ando T; Kajiura S; Yoshikawa A; Harada K; Hatanaka K; Tanimoto A; Ishiguro A; Honda T; Dazai M; Sasaki T; Sakamoto N; Komatsu Y
    Int J Clin Oncol; 2020 Oct; 25(10):1800-1806. PubMed ID: 32666389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan.
    Maehira H; Iida H; Mori H; Nitta N; Tokuda A; Takebayashi K; Kaida S; Miyake T; Matsubara A; Tani M
    Clin J Gastroenterol; 2021 Dec; 14(6):1772-1778. PubMed ID: 34596871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
    J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.